Cephalon finishes settlement on improper-marketing charges

Cephalon agreed to five years of greater regulatory oversight on sales and promotional activities and to pay more than $400 million, settling with federal and state regulators over charges that it marketed three medicines for unapproved usage. Cephalon took measures to bolster accountability and transparency, and its policies address most of the requirements detailed in the settlement, a company executive said.

View Full Article in:

Wall Street Journal, The · American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ